Getinge (OTCMKTS:GNGBY) Upgraded at Zacks Research

Getinge (OTCMKTS:GNGBY) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Getinge Stock Performance

Shares of GNGBY stock opened at $23.96 on Tuesday. The company has a market capitalization of $6.53 billion, a price-to-earnings ratio of 22.82 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.86 and a current ratio of 1.32. The company has a 50-day simple moving average of $20.86 and a 200 day simple moving average of $21.33. Getinge has a 52 week low of $18.99 and a 52 week high of $24.67.

Getinge (OTCMKTS:GNGBY) last released its quarterly earnings results on Friday, July 17th. The company reported $0.38 earnings per share for the quarter. The firm had revenue of $894.87 million for the quarter. Getinge had a net margin of 7.81% and a return on equity of 11.67%. On average, sell-side analysts predict that Getinge will post 1.38 earnings per share for the current year.

Getinge Company Profile

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.